The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis

Alessandro Isidori; Francesco Merli; Francesco Angrilli; Felicetto Ferrara; Francesco Alesiani; Giuseppe Visani

doi:10.3109/10428194.2010.525726

The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis

Alessandro Isidori, Francesco Merli, Francesco Angrilli, Felicetto Ferrara, Francesco Alesiani, Giuseppe Visani

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	148-149
Number of pages	2
Journal	Leukemia and Lymphoma
Volume	52
Issue number	1
DOIs	https://doi.org/10.3109/10428194.2010.525726
Publication status	Published - Jan 2011

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2010.525726

Cite this

Isidori, A., Merli, F., Angrilli, F., Ferrara, F., Alesiani, F., & Visani, G. (2011). The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis. Leukemia and Lymphoma, 52(1), 148-149. https://doi.org/10.3109/10428194.2010.525726

The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis. / Isidori, Alessandro; Merli, Francesco; Angrilli, Francesco; Ferrara, Felicetto; Alesiani, Francesco; Visani, Giuseppe.

In: Leukemia and Lymphoma, Vol. 52, No. 1, 01.2011, p. 148-149.

Research output: Contribution to journal › Article › peer-review

Isidori, A, Merli, F, Angrilli, F, Ferrara, F, Alesiani, F & Visani, G 2011, 'The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis', Leukemia and Lymphoma, vol. 52, no. 1, pp. 148-149. https://doi.org/10.3109/10428194.2010.525726

Isidori A, Merli F, Angrilli F, Ferrara F, Alesiani F, Visani G. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis. Leukemia and Lymphoma. 2011 Jan;52(1):148-149. https://doi.org/10.3109/10428194.2010.525726

Isidori, Alessandro ; Merli, Francesco ; Angrilli, Francesco ; Ferrara, Felicetto ; Alesiani, Francesco ; Visani, Giuseppe. / The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis. In: Leukemia and Lymphoma. 2011 ; Vol. 52, No. 1. pp. 148-149.

@article{813771136e47415d9eb34f4ba55e4ee0,

title = "The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis",

author = "Alessandro Isidori and Francesco Merli and Francesco Angrilli and Felicetto Ferrara and Francesco Alesiani and Giuseppe Visani",

year = "2011",

month = jan,

doi = "10.3109/10428194.2010.525726",

language = "English",

volume = "52",

pages = "148--149",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis

AU - Isidori, Alessandro

AU - Merli, Francesco

AU - Angrilli, Francesco

AU - Ferrara, Felicetto

AU - Alesiani, Francesco

AU - Visani, Giuseppe

PY - 2011/1

Y1 - 2011/1

UR - http://www.scopus.com/inward/record.url?scp=78651311755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651311755&partnerID=8YFLogxK

U2 - 10.3109/10428194.2010.525726

DO - 10.3109/10428194.2010.525726

M3 - Article

C2 - 21067442

AN - SCOPUS:78651311755

VL - 52

SP - 148

EP - 149

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -

The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this